Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials
4 recruiting trials for Gastroenteropancreatic Neuroendocrine Tumor. Eligibility criteria explained in plain English.
TrialFinderData lists 4 Gastroenteropancreatic Neuroendocrine Tumor clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 3 is the largest group at 33% (1 studies); the largest phase groups are Phase 3: 1, Phase 1 / Phase 2: 1, Phase 4: 1.
Research is led by RayzeBio, Inc. (1), Perspective Therapeutics (1), University Hospital, Antwerp (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is RYZ101 (drug, 1 trial), followed by Everolimus, Sunitinib.
Track Gastroenteropancreatic Neuroendocrine Tumor trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following...
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with...
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic...
Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg...
Neuroendocrine tumors represent a heterogeneous group of tumors, of which gastrointestinal (gastroenteropancreatic) NETs are the most frequent. Therapeutic management involves...
Explore Other Conditions
Frequently Asked Questions
There are currently 4 clinical trials for Gastroenteropancreatic Neuroendocrine Tumor, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Gastroenteropancreatic Neuroendocrine Tumor, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Gastroenteropancreatic Neuroendocrine Tumor, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.